OCULAR THERAPEUTIX, INC Derivative Liability
OCULAR THERAPEUTIX, INC (OCUL) had Derivative Liability of $11.38 million as of 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2023-11-07
- 2023-09-30: Derivative Liability $11.38M.
- 2023-06-30: Derivative Liability $11.78M.
- 2023-03-31: Derivative Liability $12.91M.
- 2022-12-31: Derivative Liability $6.35M.
| Period end | Derivative Liability |
|---|---|
| 2023-09-30 | $11.38M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $11.78M 10-Q · filed 2023-11-07 |
| 2023-03-31 | $12.91M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $6.35M 10-Q · filed 2023-11-07 |
| 2022-09-30 | $11.59M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $10.46M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $13.23M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $20.19M 10-K · filed 2023-03-06 |
| 2021-09-30 | $36.06M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $59.90M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $73.30M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $98.31M 10-K · filed 2023-03-06 |
| 2020-09-30 | $28.76M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $32.53M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $15.53M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $12.12M 10-K · filed 2022-02-28 |
| 2019-09-30 | $9.10M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $13.07M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $11.46M 10-Q · filed 2019-05-10 |
| 2019-03-01 | $14.69M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |